Immuneering Expands Board of Directors with Appointment of Ann E. Berman CAMBRIDGE, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation ("Immuneering"), a private biopharmaceutical company advancing a robust pipeline of oncology and neuroscience drug candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the appointment of Ann E. Berman, retired Vice President of Finance and Chief Financial Officer of Harvard University, to its Board of Directors. Ms. Berman will Chair the Audit Committee. "Ann brings a wealth of highly relevant board experience and financial expertise to the Immuneering Board, and we''re honored to have her join our team," stated Bob Carpenter, Immuneering Co-Founder and Chairman of its Board of Directors. "We appreciate Ann serving as a director and look forward to benefiting from her judgment and counsel." "Immuneering is developing novel product candidates that have the potential to change the way we treat cancer and neurological diseases, and I am incredibly excited to be able to join and contribute to the Board at such a pivotal time in the company''s journey to advance these breakthroughs from bench to bedside," said Ms.